Mifepristone With Buccal Misoprostol for Medical Abortion

Obstetrics and Gynecology

Volumn 126, Issue 1, 2015, Pages 12-21

  Chen, Melissa J ^a   Creinin, Mitchell D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE; MISOPROSTOL; ABORTIVE AGENT;

BLOOD TRANSFUSION; CHILL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FEVER; GESTATIONAL AGE; GESTATIONAL SAC; HOSPITALIZATION; HUMAN; MEDICAL ABORTION; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; PREGNANCY TERMINATION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ADVERSE EFFECTS; BUCCAL DRUG ADMINISTRATION; DRUG ADMINISTRATION; DRUG COMBINATION; FIRST TRIMESTER PREGNANCY; INDUCED ABORTION; PROCEDURES;

ABORTIFACIENT AGENTS; ABORTION, INDUCED; ADMINISTRATION, BUCCAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIFEPRISTONE; MISOPROSTOL; PREGNANCY; PREGNANCY TRIMESTER, FIRST;

EID: 84932147703     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000897     Document Type: Review

References (33)

1. Jones RK, Jerman J. Abortion incidence and service availability in the United States, 2011. Perspect Sex Reprod Health 2014; 46:3-14.
2. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241-7.
3. Medical management of first-trimester abortion. Practice Bulletin No. 143. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:676-92.
4. Medical management of first-trimester abortion. Contraception 2014;89:148-61.
5. Royal College of Obstetricians and Gynaecologists. The care of women requesting induced abortion: evidence-based clinical guideline number 7. 3rd ed. London (UK): RCOG Press; 2011.
6. Fischer M, Bhatnagar J, Guarner J, Reagan S, Hacker JK, Van Meter SH, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005;353:2352-60.
7. Trussell J, Nucatola D, Fjerstad M, Lichtenberg ES. Reduction in infection-related mortality since modifications in the regimen of medical abortion. Contraception 2014;89:193-6.
8. Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002;17:332-6.
9. Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD. Misoprostol administered by epithelial routes: drug absorption and uterine response. Obstet Gynecol 2006;108: 582-90.
10. Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception 2005;71:22-5.
11. Middleton T, Schaff E, Fielding SL, Scahill M, Shannon C, Westheimer T, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception 2005;72:328-32.
12. Lohr PA, Reeves MF, Hayes JL, Harwood B, Creinin MD. Oral mifepristone and buccal misoprostol administered simultaneously for abortion: a pilot study. Contraception 2007;76: 215-20.
13. Alam A, Bracken H, Johnston HB, Raghavan S, Islam N, Winikoff B, et al. Acceptability and feasibility of mifepristonemisoprostol for menstrual regulation in Bangladesh. Int Perspect Sex Reprod Health 2013;39:79-87.
14. Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhea in a general practice in Curacao. Eur J Contracept Reprod Health Care 2011;16:61-6.
15. Winikoff B, Dzuba IG, Chong E, Goldberg AB, Lichtenberg ES, Ball C, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol 2012;120:1070-6.
16. Peña M, Dzuba IG, Smith PS, Mendoza LJ, Bousiéguez M, Martinez ML, et al. Efficacy and acceptability of a mifepristonemisoprostol combined regimen for early induced abortion among women in Mexico City. Int J Gynaecol Obstet 2014;127:82-5.
17. Giri A, Tuladhar H, Tuladhar AS, Maharjan M, Dhakal N. Prospective study of medical abortion in Nepal Medical College Teaching Hospital (NMCTH). A one year experience. Nepal Med Coll J 2011;13:213-5.
18. Ngoc NT, Blum J, Raghavan S, Nga NT, Dabash R, Diop A, et al. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception 2011;83:410-7.
19. Blum J, Raghavan S, Dabash R, Ngoc NT, Chelli H, Hajri S. Comparison of misoprostol-only and combined mifepristonemisoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet 2012;118:166-71.
20. Dahiya K, Ahuja K, Dhingra A, Duhan N, Nanda S. Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion. Arch Gynecol Obstet 2012;285:1055-8.
21. Raghavan S, Comendant R, Digol I, Ungureanu S, Dondiuc I, Turcanu S, et al. Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception 2010;82:513-9.
22. Fjerstad M, Sivin I, Lichtenberg ES, Trussell J, Cleland K, Cullins V. Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days. Contraception 2009;80:282-6.
23. Chai J, Wong CY, Ho PC. A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception 2013;87:480-5.
24. Winikoff B, Dzuba IG, Creinin MD, Crowden WA, Goldberg AB, Gonzales J, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol 2008;112:1303-10.
25. Grossman D, Grindlay K, Buchacker T, Lane K, Blanchard K. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol 2011; 118:296-303.
26. Goldstone P, Michelson J, Williamson E. Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study. Med J Aust 2012; 197:282-6.
27. Ngo TD, Park MH, Xiao Y. Comparing the World Health Organization-versus China-recommended protocol for firsttrimester medical abortion: a retrospective analysis. Int J Womens Health 2012;4:123-7.
28. Louie KS, Tsereteli T, Chong E, Aliyeva F, Rzayeva G, Winikoff B. Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan. Eur J Contracept Reprod Health Care 2014;19:457-64.
29. Ngoc NT, Bracken H, Blum J, Nga NT, Minh NH, van Nhang N, et al. Acceptability and feasibility of phone followup after early medical abortion in Vietnam: a randomized controlled trial. Obstet Gynecol 2014;123:88-95.
30. Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015;91:269-73.
31. Chong E, Tsereteli T, Nguyen NN, Winikoff B. A randomized controlled trial of different buccal misoprostol doses in the mifepristone medical abortion. Contraception 2012;86:251-6.
32. Reeves MF, Kudva A, Creinin MD. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. Contraception 2008;78:332-5.
33. Creinin MD, Danielsson KG. Medical abortion in early pregnancy. In: Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, Creinin MD, editors. Management of unintended and abnormal pregnancy: comprehensive abortion care. 1st ed. Hoboken (NJ): Wiley-Blackwell; 2009. p. 111-34.